Surrozen, Inc. (SRZN) - Q1 2025 Filing Summary
Business Context and Reporting Period
This summary covers the Unaudited Condensed Consolidated Financial Statements for Surrozen, Inc. for the quarterly period ended March 31, 2025. Surrozen is a biotechnology company focused on discovering and developing drug candidates to selectively modulate the Wnt pathway, with a current strategic focus on ophthalmology. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0.98 million | $0 |
| Net Loss | $(27.0) million | $(8.8) million |
| Net Loss Per Share (Basic & Diluted) | $(7.43) | $(4.24) |
| Cash and Cash Equivalents | $101.6 million | $27.3 million |
| Total Assets | $114.8 million | $48.5 million |
| Total Liabilities | $109.2 million | $69.8 million |
| Stockholders' Equity | $5.7 million | $(21.4) million |
| Operating Cash Flow | $(9.3) million | $(8.7) million |
| Financing Cash Flow | $76.4 million | $0 |
Material Changes vs. Prior Period
- Capital Raise (2025 PIPE): In March 2025, the company executed a two-tranche private placement (2025 PIPE). The first tranche closed on March 26, 2025, generating net proceeds of approximately $71.3 million. This significantly increased cash reserves from $34.6 million at year-end 2024 to $101.6 million.
- Accounting Impact of PIPE: The execution of the 2025 PIPE resulted in a non-cash loss of $71.1 million recorded as "Loss on execution of the 2025 PIPE" because the fair value of the tranche liability exceeded the committed proceeds from the first tranche. Additionally, a gain of $16.3 million was recognized on the change in fair value of the tranche liability, and a gain of $1.1 million on the settlement of the tranche liability.
- Warrant Adjustments: The company amended and cancelled certain 2024 PIPE warrants (Series C and D) due to the discontinuation of the SZN-043 program. This resulted in a non-cash loss of $2.1 million.
- Revenue Recognition: The company recognized $0.98 million in research service revenue from a related party (TCGFB, Inc.), compared to zero in the prior year.
- Operating Expenses: Total operating expenses increased 15% to $10.5 million, driven by a 25% increase in R&D expenses ($6.6 million) due to manufacturing costs for SZN-043 prior to its discontinuation and increased consulting fees for ophthalmology programs.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash and cash equivalents ($101.6 million) are sufficient to fund operations for at least the next 12 months. The second tranche of the 2025 PIPE, expected to raise approximately $98.6 million, is contingent upon FDA clearance of the Investigational New Drug (IND) application for SZN-8141 by October 31, 2026.
- Pipeline Updates:
- SZN-043: Discontinued in Q1 2025 for severe alcohol-associated hepatitis due to insufficient early clinical benefit signals.
- SZN-8141 & SZN-8143: Lead candidates for retinal diseases (DME, wet AMD). The company expects to file an IND for SZN-8141 in 2026.
- SZN-413: In collaboration with Boehringer Ingelheim; a $10.0 million milestone was triggered in September 2024.
- Risks:
- Capital Requirements: The company expects to continue incurring significant losses and will require substantial additional capital to advance clinical trials and commercialization.
- Regulatory Uncertainty: No product candidates have received regulatory approval. Success depends on IND clearance and positive clinical trial results.
- Market Volatility: The company's stock price and warrant liabilities are subject to significant volatility based on clinical data, financing activities, and market conditions.
- Trade Policy: Potential impact of new tariffs on imports from the UK (where contract manufacturing occurs) and other nations.
Investor Verification Checklist
- Verify Tranche Liability Terms: Confirm the specific milestones and conditions required to trigger the second tranche of the 2025 PIPE ($98.6 million) and the implications if the SZN-8141 IND is not cleared by October 31, 2026.
- Assess Warrant Liability Exposure: Review the fair value assumptions (volatility, term) for the significant warrant liabilities ($49.4 million) and tranche liability ($42.4 million) on the balance sheet, as changes in these values directly impact net income.
- Monitor Cash Burn Rate: Track quarterly operating cash burn against the $101.6 million cash balance to validate the 12-month runway assertion.
- Review Related Party Transactions: Examine the terms of the collaboration with TCGFB, Inc. and the sublease with Nura Bio, Inc., given the involvement of board members and significant stockholders.
- Confirm SZN-8141 Timeline: Verify the company's progress toward the 2026 IND filing target for SZN-8141, which is critical for future funding.